

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/634,645	08/05/2003	Mauricio Rojas	60068.0002US01	7190
7590 10/14/2004 TIM TINGKANG XIA MORRIS, MANNING & MARTIN, LLP 1600 ATLANTA FINANCIAL CENTER 3343 PEACHTREE ROAD, N.E. ATLANTA, GA 30326-1044			EXAMINER	
			SWARTZ, RODNEY P	
			ART UNIT	PAPER NUMBER
			1645	
			DATE MAILED: 10/14/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		10/634,645	ROJAS ET AL.			
		Examiner	Art Unit			
		Rodney P. Swartz, Ph.D.	1645			
Period fo	The MAILING DATE of this communication or Reply	appears on the cover sheet wit	h the correspondence address			
THE - Exte after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR RE MAILING DATE OF THIS COMMUNICATIO nsions of time may be available under the provisions of 37 CFF SIX (6) MONTHS from the mailing date of this communication e period for reply specified above is less than thirty (30) days, a period for reply is specified above, the maximum statutory pere to reply within the set or extended period for reply will, by streply received by the Office later than three months after the med patent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no event, however, may a re reply within the statutory minimum of thirty riod will apply and will expire SIX (6) MONT atute, cause the application to become ABA	ply be timely filed  (30) days will be considered timely.  (HS from the mailing date of this communication.  ANDONED (35 U.S.C. § 133).			
Status						
1)[	Responsive to communication(s) filed on					
2a) <u></u>	This action is <b>FINAL</b> . 2b) ☐ This action is non-final.					
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Dispositi	ion of Claims					
5) 6) 7)	Claim(s) <u>1-88</u> is/are pending in the applicat 4a) Of the above claim(s) is/are with Claim(s) is/are allowed.  Claim(s) is/are rejected.  Claim(s) is/are objected to.  Claim(s) <u>1-88</u> are subject to restriction and/	drawn from consideration.				
Applicati	on Papers					
9)[	The specification is objected to by the Exam	niner.				
10)	10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
	Applicant may not request that any objection to	- · ·	· ·			
11)	Replacement drawing sheet(s) including the cor The oath or declaration is objected to by the	•	•			
Priority ι	ınder 35 U.S.C. § 119					
12)[_ a)[	Acknowledgment is made of a claim for fore  All b) Some * c) None of:  1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the papplication from the International Bur See the attached detailed Office action for a	ents have been received. ents have been received in Appriority documents have been reeau (PCT Rule 17.2(a)).	oplication No received in this National Stage			
Attachmen	t(s)					
1) Notic	e of References Cited (PTO-892)	4) 🔲 Interview Su				
3) 🔲 Inforr	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/ r No(s)/Mail Date		/Mail Date formal Patent Application (PTO-152) 			

## **DETAILED ACTION**

## **Election/Restrictions**

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-16, drawn to fusion proteins, classified in class 424, subclass 192.1.
  - II. Claims 17-86, drawn to methods of immunizing/treatment, classified in class 424, subclass 9.2.
  - III. Claims 87-88, drawn to animal model, classified in class 800, subclass 9.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the proteins of Invention I can be utilized *in vitro* for facilitating entry of polypeptides and proteins into cultured cells.

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the proteins of Invention I can be utilized *in vitro* for facilitating entry of polypeptides and proteins into cultured cells.

Inventions II and III are drawn to patentably distinct inventions. Invention II is drawn to methods of treatment of subjects with immune-related disorders and methods of preventing

Application/Control Number: 10/634,645

Art Unit: 1645

immune responses in subjects. Invention III is an animal model for comparing levels of reporter gene products.

Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification, and because while the searches may overlap, the searches are not coextensive, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Thursday from 5:30 AM to 4:00 PM EST.

If attempts to reach the Examiner by telephone are unsuccessful, the examiner's supervisor, Lynette F. Smith, can be reached on (571)272-0864.

The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Application/Control Number: 10/634,645

Art Unit: 1645

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

RODNEY P SWARTZ, PH. I PRIMARY EXAMINER Art Unit 1645

October 6, 2004